|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 41018 |
FusionGeneSummary for USP22_RUSC2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: USP22_RUSC2 | Fusion gene ID: 41018 | Hgene | Tgene | Gene symbol | USP22 | RUSC2 | Gene ID | 23326 | 9853 |
| Gene name | ubiquitin specific peptidase 22 | RUN and SH3 domain containing 2 | |
| Synonyms | USP3L | Iporin|MRT61 | |
| Cytomap | 17p11.2 | 9p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ubiquitin carboxyl-terminal hydrolase 22deubiquitinating enzyme 22ubiquitin specific protease 22ubiquitin thioesterase 22ubiquitin thiolesterase 22ubiquitin-specific processing protease 22 | iporinRUN and SH3 domain-containing protein 2interacting protein of Rab1 | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | Q9UPT9 | Q8N2Y8 | |
| Ensembl transtripts involved in fusion gene | ENST00000261497, ENST00000537526, ENST00000455117, | ENST00000455600, ENST00000468041, | |
| Fusion gene scores | * DoF score | 14 X 9 X 5=630 | 4 X 4 X 2=32 |
| # samples | 19 | 5 | |
| ** MAII score | log2(19/630*10)=-1.72935241005633 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/32*10)=0.643856189774725 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: USP22 [Title/Abstract] AND RUSC2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | USP22 | GO:0016574 | histone ubiquitination | 18469533 |
| Hgene | USP22 | GO:0016578 | histone deubiquitination | 18206972|18206973 |
| Hgene | USP22 | GO:0016579 | protein deubiquitination | 16378762 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BF821260 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + | ||
| ChiTaRS3.1 | BF900662 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000261497 | ENST00000455600 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| intron-intron | ENST00000261497 | ENST00000468041 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| intron-3CDS | ENST00000537526 | ENST00000455600 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| intron-intron | ENST00000537526 | ENST00000468041 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| intron-3CDS | ENST00000455117 | ENST00000455600 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
| intron-intron | ENST00000455117 | ENST00000468041 | USP22 | chr17 | 20919165 | + | RUSC2 | chr9 | 35555682 | + |
Top |
FusionProtFeatures for USP22_RUSC2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| USP22 | RUSC2 |
| Histone deubiquitinating component of the transcriptionregulatory histone acetylation (HAT) complex SAGA. Catalyzes thedeubiquitination of both histones H2A and H2B, thereby acting as acoactivator. Recruited to specific gene promoters by activatorssuch as MYC, where it is required for transcription. Required fornuclear receptor-mediated transactivation and cell cycleprogression. {ECO:0000269|PubMed:18206972,ECO:0000269|PubMed:18206973, ECO:0000269|PubMed:18469533}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for USP22_RUSC2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for USP22_RUSC2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for USP22_RUSC2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for USP22_RUSC2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|